25,147 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC bought a new position in Schrödinger, Inc. (NASDAQ:SDGR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 25,147 shares of the company’s stock, valued at approximately $485,000.

Other institutional investors also recently bought and sold shares of the company. Envestnet Asset Management Inc. grew its position in shares of Schrödinger by 6.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 185,754 shares of the company’s stock valued at $3,583,000 after purchasing an additional 11,343 shares during the period. ExodusPoint Capital Management LP purchased a new stake in Schrödinger in the 4th quarter valued at about $280,000. Massachusetts Financial Services Co. MA increased its stake in shares of Schrödinger by 17.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 2,279,313 shares of the company’s stock valued at $43,968,000 after acquiring an additional 334,131 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Schrödinger by 13.7% during the 4th quarter. Franklin Resources Inc. now owns 20,051 shares of the company’s stock worth $387,000 after acquiring an additional 2,412 shares during the period. Finally, Norges Bank acquired a new stake in shares of Schrödinger in the fourth quarter worth approximately $1,546,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Geoffrey Craig Porges sold 5,491 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $21.76, for a total value of $119,484.16. Following the completion of the sale, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at $599,357.44. The trade was a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SDGR shares. KeyCorp lifted their price target on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Piper Sandler dropped their target price on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Schrödinger currently has a consensus rating of “Buy” and an average price target of $32.29.

Schrödinger Trading Down 4.5 %

Shares of SDGR stock opened at $18.03 on Monday. Schrödinger, Inc. has a twelve month low of $16.67 and a twelve month high of $29.15. The company has a market capitalization of $1.32 billion, a PE ratio of -7.71 and a beta of 1.77. The firm has a fifty day simple moving average of $22.74 and a 200-day simple moving average of $20.75.

Schrödinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The business had revenue of $88.32 million for the quarter, compared to analyst estimates of $83.20 million. Equities research analysts predict that Schrödinger, Inc. will post -2.37 EPS for the current year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.